The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Sarepta Therapeutics Inc. (SRPT) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$4.59, or -4.03%, to $109.31. Volume reached 19,893 shares, with price reaching a high of $110.14 and a low of $109.32. Most recently, Yahoo Finance reported about the stock as it publicized that Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027.
Sarepta Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $110.14 and fluctuated between $115.40 as its day high and $110.07 as its day low. The current market capitalization of Sarepta Therapeutics Inc. is $9.53B. A total of 1.02 million shares were traded on the day, compared to an average of 1.12M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, SRPT has seen 2 BUY and 0 SELL insider trades, representing the acquisition of 46,170 and the disposition of 0 shares. Over the last 12 months, there were 20 BUYs and 10 SELLs from insiders. Insiders purchased 184,769 shares during that period but sold 6,557.
In the most recent transaction, Chambers Michael Andrew bought 57,100 shares of SRPT for 104.43 per share on Sep 14. After the transaction, the Director now owns 108,178 company shares. In a previous transaction on Aug 19, Chambers Michael Andrew bought 46,170 shares at 108.28 per share. SRPT shares that Director owns now total 51,078.
Among the insiders who bought shares, Rodino-Klapac Louise acquired of 3,780 shares on Nov 24 at a per-share price of $79.33. This resulted in the Head of R&D, CSO holding 65,678 shares of SRPT after the transaction. In another insider transaction, INGRAM DOUGLAS S bought 25,026 shares at $79.94 per share on Nov 17. Company shares held by the President & CEO now total 365,082.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for SRPT in the last 3 months, the mean price target is $130.50 with high estimates of $182.00 and low estimates of $93.00. In terms of 52-week highs and lows, SRPT has a high of $120.23 and a low of $61.28.
As of this writing, SRPT has an earnings estimate of $-1.36 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $-0.81 per share and a lower estimate of $-2.31. The company reported an EPS of $-2.65 in the last quarter, which was -147.66% lower than expectations of $-1.07.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. SRPT’s latest balance sheet shows that the firm has $2.12B in Cash & Short Term Investments as of fiscal 2021. There were $1.14B in debt and $452.73M in liabilities at the time. Its Book Value Per Share was $8.30, while its Total Shareholder’s Equity was $928.01M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 21 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SRPT is Sell with a score of 4.50. A total of 14 analysts rated the stock as Buy while 2 rated it as Overweight while 5 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.